,11 Although osimertinib is frequently used for its potential beneficial outcomes in first- and late-line settings, almost all patients with EGFR-mutant lung cancer ultimately acquired resistance to osimertinib after approximately 20 months.10 This evidence concerns the gene EGFR and lung carcinoma.